The rise of Sildenafil initially sparked a period of growth for pharma, however recent developments present a murky scenario for shareholders. Off-patent competitors are eroding revenue, and continued patent challenges https://joanqkio517572.thekatyblog.com/39371231/sildenafil-and-pharma-a-volatile-bet